Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 18 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Prostatic Neoplasms, Castration-Resistant Phase 1 Australia
South Africa

A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy.

Metastatic Castration-resistant Prostate Cancer (mCRPC) Phase 1, Phase 2 France

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2-, GRPR+ Breast Cancer

Breast Cancer Phase 1 Spain
Portugal
France

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Phase 1 United States
France
Belgium
Germany
Japan
Spain
Korea, Republic of
Singapore
Taiwan
Israel
View All

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Early Breast Cancer Phase 3 Australia

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Prostate Cancer Phase 4 United States

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

Breast Cancer France

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 2 China

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Advanced Breast Cancer Phase 4 India

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms Phase 1 United States
Spain
Japan
Germany
Hong Kong
Singapore
Taiwan
Canada
View All